F m Investments LLC Sells 27,658 Shares of Travere Therapeutics, Inc. $TVTX

F m Investments LLC trimmed its holdings in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) by 14.1% in the fourth quarter, Holdings Channel.com reports. The firm owned 168,416 shares of the company’s stock after selling 27,658 shares during the quarter. F m Investments LLC’s holdings in Travere Therapeutics were worth $6,435,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of TVTX. Torren Management LLC bought a new position in shares of Travere Therapeutics during the 4th quarter worth approximately $38,000. Comerica Bank boosted its holdings in shares of Travere Therapeutics by 77.5% in the 4th quarter. Comerica Bank now owns 1,127 shares of the company’s stock valued at $43,000 after buying an additional 492 shares during the last quarter. First Horizon Corp acquired a new stake in shares of Travere Therapeutics in the 3rd quarter valued at approximately $36,000. Garner Asset Management Corp acquired a new stake in shares of Travere Therapeutics in the 4th quarter valued at approximately $69,000. Finally, Raymond James Financial Inc. acquired a new stake in shares of Travere Therapeutics in the 2nd quarter valued at approximately $33,000.

Analyst Upgrades and Downgrades

TVTX has been the subject of several recent analyst reports. Canaccord Genuity Group increased their price objective on Travere Therapeutics from $47.00 to $56.00 and gave the company a “buy” rating in a report on Tuesday, April 14th. JPMorgan Chase & Co. cut their price objective on Travere Therapeutics from $44.00 to $41.00 and set an “overweight” rating for the company in a report on Wednesday, March 25th. Citigroup increased their price objective on Travere Therapeutics from $53.00 to $59.00 and gave the company a “buy” rating in a report on Tuesday. HC Wainwright increased their price objective on Travere Therapeutics from $47.00 to $57.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Wedbush raised their price target on Travere Therapeutics from $53.00 to $55.00 and gave the company an “outperform” rating in a report on Tuesday. Ten investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Travere Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $47.83.

Travere Therapeutics Stock Down 0.1%

Shares of NASDAQ TVTX opened at $42.60 on Friday. The company has a debt-to-equity ratio of 3.16, a quick ratio of 2.70 and a current ratio of 3.13. Travere Therapeutics, Inc. has a 52 week low of $13.88 and a 52 week high of $48.61. The stock has a market capitalization of $3.96 billion, a P/E ratio of -185.21 and a beta of 1.13. The stock’s fifty day moving average is $32.83 and its 200 day moving average is $32.94.

Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings results on Monday, May 4th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.29. Travere Therapeutics had a negative return on equity of 26.16% and a negative net margin of 4.00%.The company had revenue of $127.20 million for the quarter, compared to analysts’ expectations of $136.23 million. During the same quarter last year, the business earned ($0.47) earnings per share. Travere Therapeutics’s revenue was up 55.6% on a year-over-year basis. Sell-side analysts forecast that Travere Therapeutics, Inc. will post -0.24 earnings per share for the current fiscal year.

Travere Therapeutics News Summary

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: Analysts remain bullish on Travere Therapeutics, with recent price target hikes to as high as $60 and continued Buy/Overweight ratings supporting the stock. Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $60.00
• Positive Sentiment: Q1 results beat EPS expectations and revenue grew 55.6% year over year, reinforcing the bullish analyst case and investor optimism. Travere Therapeutics, Inc. 2026 Q1 – Results – Earnings Call Presentation
• Positive Sentiment: Travere will present at several upcoming healthcare investor conferences, which could increase visibility and keep momentum around the stock. Travere Therapeutics to Participate at Upcoming Investor Conferences
• Neutral Sentiment: The company priced an upsized $475 million convertible senior notes offering to refinance 2029 notes, improving balance-sheet flexibility but creating potential future dilution. Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
• Neutral Sentiment: HC Wainwright trimmed earnings estimates slightly but kept a Buy rating and a $57 target, so the outlook remains supportive overall. Wells Fargo & Company Issues Positive Forecast for Travere Therapeutics (NASDAQ:TVTX) Stock Price
• Negative Sentiment: Multiple insiders, including the CEO, CFO, directors, and executives, disclosed recent stock sales, which can create near-term concern even though many were tied to tax withholding and 10b5-1 plans. Jula Inrig Sells 20,000 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock

Insider Buying and Selling

In other Travere Therapeutics news, insider Jula Inrig sold 20,000 shares of Travere Therapeutics stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $45.00, for a total value of $900,000.00. Following the transaction, the insider owned 111,473 shares in the company, valued at $5,016,285. The trade was a 15.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Sandra Calvin sold 21,977 shares of Travere Therapeutics stock in a transaction dated Tuesday, April 14th. The shares were sold at an average price of $41.07, for a total value of $902,595.39. Following the completion of the transaction, the chief accounting officer owned 42,353 shares in the company, valued at approximately $1,739,437.71. This represents a 34.16% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 400,015 shares of company stock valued at $15,895,428 in the last ninety days. Insiders own 4.44% of the company’s stock.

Travere Therapeutics Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.